This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Abeona Therapeutics, Inc.

Drug Names(s): EB101, EB 101, LZRSE-COL7A1

Description: EB-101 is an ex vivo gene therapy used to prepare type VII collagen gene-corrected skin grafts. The inherited disease, dystrophic epidermolysis bullosa, is caused by recessive or dominant mutations in COL7A1, the gene encoding type VII collagen.

EB-101 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug